Study Comparing Two Doses of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer

Sponsor: AstraZeneca

Sponsor score: 40

ClinicalTrials ID:NCT00099437

Provider View

This clinical trial is testing whether a higher dose of Fulvestrant (500 mg) is more effective than the standard dose (250 mg) for treating postmenopausal women with advanced breast cancer that has not responded to previous hormone therapy.

Patient Parameters

Program Overview

The study aims to find out if a higher dose of Fulvestrant (500 mg) works better than the usual dose (250 mg) in treating postmenopausal women with advanced breast cancer that is estrogen receptor positive and has not improved with previous hormone treatments.

Eligibility Criteria

Inclusion Criteria

  • Breast cancer has continued to grow after treatment with hormone therapies like tamoxifen or aromatase inhibitors.
  • Need for hormone treatment.
  • Women who have stopped having menstrual periods (postmenopausal).
  • Cancer shows sensitivity to estrogen hormones.
  • Willingness to sign a consent form to participate in the study.

Exclusion Criteria

  • Have taken an experimental or non-approved drug in the last month.
  • Have a serious illness or condition that would prevent participation in the study.
  • Have allergies to any ingredients in Faslodex, such as castor oil.
  • Have had more than one chemotherapy treatment for advanced breast cancer.
  • Have had more than one hormone treatment for advanced breast cancer.

Locations

FACILITYZIPCITYSTATE
Research Site85122Casa GrandeArizona
Research Site92708Fountain ValleyCalifornia
Research Site06052New BritainConnecticut
Research Site34429Crystal RiverFlorida
Research Site33308Fort LauderdaleFlorida
Research Site61801UrbanaIllinois
Research Site21237RosedaleMaryland
Research Site48202DetroitMichigan
Research Site64131Kansas CityMissouri
Research Site63141St LouisMissouri

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.